ATG9B Antikörper (AA 110-121) (PE)
Kurzübersicht für ATG9B Antikörper (AA 110-121) (PE) (ABIN5066225)
Target
Alle ATG9B Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 110-121
-
Spezifität
- Highly expressed in placenta (trophoblast cells) and pituitary gland. Not expressed in vascular endothelial.,Detects ~100 kDa.
-
Kreuzreaktivität
- Human, Maus
-
Aufreinigung
- Peptide Affinity Purified
-
Immunogen
- Synthetic peptide from the N-terminal of Human ATG9B (aa. 110-121)
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
- WB (1:1000)
- ICC/IF (1:100)
- optimal dilutions for assays should be determined by the user.
-
Kommentare
-
A 1:1000 dilution of ABIN5066225 was sufficient for detection of ATG9B in 15 μg of Human HeLa Cell Lysates by ECL immunoblot analysis using goat anti-rabbit IgG:HRP as the secondary antibody.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 mg/mL
-
Buffer
- PBS, 50 % glycerol, 0.09 % sodium azide, Storage buffer may change when conjugated
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- 4 °C
-
Informationen zur Lagerung
- Conjugated antibodies should be stored at 4°C
-
-
- ATG9B (Autophagy Related 9B (ATG9B))
-
Andere Bezeichnung
- ATG9B
-
Hintergrund
- ATG9B is involved in autophagy and cytoplasm to vacuole transport (Cvt) vesicle formation. Plays a key role in the organization of the preautophagosomal structure/phagophore assembly site (PAS), the nucleating site for formation of the sequestering vesicle. Highly expressed in the placenta and the pituitary gland.
-
Gen-ID
- 285973
-
NCBI Accession
- NP_001303985
-
UniProt
- Q674R7
Target
-